Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care, Biosensors and Mobile Diagnostics Europe 2022

Mark Bradley's Biography



Mark Bradley, Professor of Therapeutic Innovation, Precision Healthcare University Research Institute, Queen Mary University of London

Mark received his doctorate from the University of Oxford in 1989, followed by post-doctoral studies at Harvard and returning to the UK as a Royal Society University Research Fellow (University of Southampton). In 1997 he was made a Professor of Combinatorial Chemistry setting up the UK’s Centre for Combinatorial Chemistry. In 2005 he moved to the University of Edinburgh, where he was Director of a £15M Interdisciplinary Research Collaboration in the area of Optical Molecular Imaging (Proteus 2014-2023) and a Doctorial Training Centre (60PhD) in Optical Imaging with Entrepreneurship. In Aug 2023 he moved to Queen Mary University of London as Professor of Therapeutic Innovation and part of the Precision Healthcare university Research Institute. He held an ERC Advanced Grant on “SmartMaterials” for cellular control. He is a co-founder of Ilika Technologies (2004) (which floated on AIMS in 2010), DestiNA Technologies (2010) and Edinburgh Molecular Imaging (2014) and Biocaptiva (2021).

Mark Bradley Image

Optical Molecular Sensing and Imaging of Cancer

Wednesday, 22 June 2022 at 12:00

Add to Calendar ▼2022-06-22 12:00:002022-06-22 13:00:00Europe/LondonOptical Molecular Sensing and Imaging of CancerPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

In my talk I will describe a number of technologies that have come out of the Proteus project that has, as its focus, the use of light (of a variety of flavors) to sense and image disease. This includes:
(i). The use of optical fibers for measuring pH around tumors;
(ii). The application of chemical probes that can paint disease (bacterial infection and cancer will be illustrated);
(iii). The use of novel CMOS SPAD detectors that allows for rapid full spectral fluorescent lifetime imaging to be used in the analysis of cancerous tissues (targeting cancer margin detection).


Add to Calendar ▼2022-06-21 00:00:002022-06-22 00:00:00Europe/LondonPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2022Point-of-Care, Biosensors and Mobile Diagnostics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com